The potential health risks associated with exposure to Stachybotrys charta rum are currently the subject of intense research, however species-specific detection of the fungus using immunoassays is not available. The purpose of this study was to use the Halogen Inununoassay (HIA) to characterize the antibody binding sites of a recently developed S. chartarum monoclonal antibody (mAb 9B4), in pre- and post-germinated conidia. Antigen expression was detected using mAb 9B4 in the IDA. Aerosolized conidia and fungal fragments were collected onto protein binding membranes direct from sporulating in vitro culture plates. To germinate conidia, samples were incubated in high humidity at room temperature for 48 hours. Ungerminated and germinated samples were then laminated with an adhesive coverslip and immunostained by the HIA. The samples were examined by confocal and light microscopy and positive (haloed) particles were expressed as percentages of total spores. The localization of specific mAb 9B4 binding sites in all pre- and post- germinated samples was primarily restricted to the conidiogenous phialides and around phialoconidia. Post-germination, the proportion of phialides releasing antigen remained unchanged (95.3 +/- 1.5) from ungerminated treatments (96.9 +/- 1.1; P=0.384); however there was a significant increase (P<0.0001) in the proportion of germinated spores expressing antigen (53.3 +/- 2.9) compared to ungerminated spores (6.6 +/- 1.1). No immunostaining was detected in either hyphal fragments or hyphae from germinated spores in pre- and post-germinated treatments. This study further supports that mAb 9B4 recognizes a sporulation specific antigen localized in the phialides and phialoconidia that can be used for Stachybotrys-specific immunoassays.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.